Loading
The randomised trial behind CAPTEM: adding capecitabine to temozolomide lengthened the time before pancreatic neuroendocrine tumours grew.
E2211, trial NCT01824875 run by the ECOG-ACRIN Cancer Research Group with the National Cancer Institute, randomised 144 patients with advanced pancreatic neuroendocrine tumours between April 2013 and March 2016 to temozolomide alone or capecitabine with temozolomide (CAPTEM). At the interim analysis in January 2018 the median progression-free survival was 14.4 months with temozolomide and 22.7 months with the combination (hazard ratio 0.58), which met the primary endpoint; at the final analysis in May 2021 overall survival did not differ significantly (53.8 vs 58.7 months, hazard ratio 0.82). MGMT deficiency was associated with response. ECOG-ACRIN ran the trial; the two medicines are generic.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
Shares Capecitabine + temozolomide (CAPTEM), Pancreatic neuroendocrine tumours, Temozolomide, Neuroendocrine tumours.
Shares Pancreatic neuroendocrine tumours, Neuroendocrine tumours.
Shares Pancreatic neuroendocrine tumours, Temozolomide, Neuroendocrine tumours.
Shares Pancreatic neuroendocrine tumours, Neuroendocrine tumours.
Shares Pancreatic neuroendocrine tumours, Neuroendocrine tumours.
Shares Pancreatic neuroendocrine tumours, Neuroendocrine tumours.
Shares Pancreatic neuroendocrine tumours, Neuroendocrine tumours.
Shares Pancreatic neuroendocrine tumours, Neuroendocrine tumours.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/